{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:39:20Z","timestamp":1761597560850},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.euroneuro.2014.11.011","type":"journal-article","created":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T01:36:28Z","timestamp":1417311388000},"page":"51-59","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: Multilocus interaction in the mTOR pathway"],"prefix":"10.1016","volume":"25","author":[{"given":"S.","family":"Mas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Gass\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Malagelada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lafuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2014.11.011_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/tpj.2011.57","article-title":"Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population","volume":"13","author":"Almoguera","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0140-6736(00)02221-2","article-title":"Pharmacogenetic prediction of clozapine response","volume":"355","author":"Arranz","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib3","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.pnpbp.2004.06.017","article-title":"Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain","volume":"28","author":"Bobes","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neuropharm.2013.04.043","article-title":"Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32kDa and inhibition of protein phosphatase-1","volume":"72","author":"Bonito-Oliva","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib5","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.2174\/1381612043384123","article-title":"The use of antiparkinsonian agents in the management of drug-induced extrapyramidal symptoms","volume":"10","author":"Burgyone","year":"2004","journal-title":"Curr. Pharm. Des"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib6","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/carcin\/bgp258","article-title":"Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk","volume":"30","author":"Chen","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2105-5-49","article-title":"An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation","volume":"5","author":"Coffey","year":"2004","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fnbeh.2011.00071","article-title":"l-Dopa-induced Dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission","volume":"5","author":"Feyder","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/tpj.2009.26","article-title":"A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms","volume":"9","author":"Gass\u00f3","year":"2009","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.2147780","article-title":"D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons","volume":"250","author":"Gerfen","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib11","first-page":"16","article-title":"Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality","volume":"61","author":"Glazer","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/tpj.2008.6","article-title":"Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3\u2032-untranslated region","volume":"9","author":"Greenbaum","year":"2009","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib13","article-title":"Is the mTOR signaling cascade disrupted in Schizophrenia?","author":"Gururajan","year":"2013","journal-title":"J. Neurochem"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0269881111424929","article-title":"Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons","volume":"26","author":"Haddad","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/bioinformatics\/btf869","article-title":"Multifactor dimensionality reduction software for detecting gene\u2013gene and gene\u2013environment interactions","volume":"19","author":"Hahn","year":"2003","journal-title":"Bioinformatics"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1086\/519850","article-title":"Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach","volume":"81","author":"Huang","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2006.09.031","article-title":"Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics","volume":"90","author":"Lafuente","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.psychres.2007.08.002","article-title":"Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins\/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders","volume":"161","author":"Lafuente","year":"2008","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cmpb.2008.02.004","article-title":"Artificial neural network prediction of clozapine response with combined pharmacogenetic and clinical data","volume":"91","author":"Lin","year":"2008","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib20","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archneur.60.9.1253","article-title":"Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease","volume":"60","author":"L\u00fccking","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib21","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1523\/JNEUROSCI.3944-09.2010","article-title":"Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson\u2019s disease","volume":"30","author":"Malagelada","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/tpj.2010.91","article-title":"Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes","volume":"12","author":"Mas","year":"2012","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/YPG.0b013e32833a2234","article-title":"Genetic association of the AKT1 gene with schizophrenia in a British population","volume":"20","author":"Mathur","year":"2010","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib24","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/emmm.201201410","article-title":"5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia","volume":"4","author":"Meffre","year":"2012","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib25","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10549-010-1062-1","article-title":"Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes","volume":"125","author":"Mehta","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajhg.2009.08.006","article-title":"Epistasis and its implications for personal genetics","volume":"85","author":"Moore","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/1479-7364-2-5-318","article-title":"Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene-gene interactions in human genetics and pharmacogenomics studies","volume":"2","author":"Motsinger","year":"2006","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s002130050017","article-title":"Atypical antipsychotics: are some more atypical than others?","volume":"148","author":"Remington","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1086\/321276","article-title":"Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer","volume":"69","author":"Ritchie","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/gepi.10218","article-title":"Power of multifactor dimensionality reduction for detecting gene\u2013gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity","volume":"24","author":"Ritchie","year":"2003","journal-title":"Genet. Epidemiol."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.schres.2008.08.024","article-title":"Association between a disrupted-in-schizophrenia 1 (DISC1) single nucleotide polymorphism and schizophrenia in a combined Scandinavian case\u2013control sample","volume":"106","author":"Saetre","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib32","doi-asserted-by":"crossref","first-page":"27806","DOI":"10.1074\/jbc.M112.388413","article-title":"Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism","volume":"287","author":"Santini","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/jpet.113.207621","article-title":"Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs","volume":"347","author":"Schmidt","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib34","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/carcin\/bgt169","article-title":"The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt\/mTOR pathway in human U-87MG glioma cells","volume":"34","author":"Shin","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib36","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00439-012-1198-7","article-title":"Integration of biological networks and pathways with genetic association studies","volume":"131","author":"Sun","year":"2012","journal-title":"Hum. Genet."},{"key":"10.1016\/j.euroneuro.2014.11.011_bib37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbapap.2007.08.015","article-title":"Role of mTOR in physiology and pathology of the nervous system","volume":"1784","author":"Swiech","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib38","first-page":"34","article-title":"Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia","volume":"68","author":"Weiden","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.11.011_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/17425255.2011.532787","article-title":"Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction","volume":"7","author":"Zhang","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14003228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14003228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T10:43:54Z","timestamp":1650710634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X14003228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0924977X14003228"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.11.011","relation":{},"ISSN":["0924-977X"],"issn-type":[{"type":"print","value":"0924-977X"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: Multilocus interaction in the mTOR pathway","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}